O	0	11	Alterations	Alteration	NNS	B-NP
O	12	14	in	in	IN	B-PP
O	15	27	carbohydrate	carbohydrate	NN	B-NP
O	28	38	metabolism	metabolism	NN	I-NP
O	39	41	in	in	IN	B-PP
O	42	48	canine	canine	JJ	B-NP
B-Cancer	49	57	lymphoma	lymphoma	NN	I-NP
O	57	58	.	.	.	O

O	60	69	Following	Follow	VBG	B-PP
O	70	72	an	an	DT	B-NP
O	73	82	overnight	overnight	JJ	I-NP
O	83	87	fast	fast	NN	I-NP
O	87	88	,	,	,	O
B-Organism_substance	89	94	blood	blood	NN	B-NP
I-Organism_substance	95	102	samples	sample	NNS	I-NP
O	103	107	were	be	VBD	B-VP
O	108	116	obtained	obtain	VBN	I-VP
O	117	121	from	from	IN	B-PP
O	122	124	14	14	CD	B-NP
O	125	129	dogs	dog	NNS	I-NP
O	130	134	with	with	IN	B-PP
O	135	145	previously	previously	RB	B-NP
O	146	155	untreated	untreated	JJ	I-NP
B-Cancer	156	164	lymphoma	lymphoma	NN	I-NP
O	165	171	before	before	IN	B-PP
O	172	175	and	and	CC	B-NP
O	176	177	5	5	CD	I-NP
O	177	178	,	,	,	I-NP
O	179	181	15	15	CD	I-NP
O	181	182	,	,	,	I-NP
O	183	185	30	30	CD	I-NP
O	185	186	,	,	,	I-NP
O	187	189	45	45	CD	I-NP
O	189	190	,	,	,	I-NP
O	191	193	60	60	CD	I-NP
O	193	194	,	,	,	O
O	195	198	and	and	CC	O
O	199	201	90	90	CD	B-NP
O	202	209	minutes	minute	NNS	I-NP
O	210	219	following	follow	VBG	B-PP
O	220	222	an	an	DT	B-NP
B-Immaterial_anatomical_entity	223	234	intravenous	intravenous	JJ	I-NP
O	235	244	challenge	challenge	NN	I-NP
O	245	249	with	with	IN	B-PP
O	250	253	500	500	CD	B-NP
O	254	256	mg	mg	NN	I-NP
O	256	257	/	/	SYM	B-NP
O	257	259	kg	kg	NN	I-NP
O	260	268	dextrose	dextrose	NN	I-NP
O	268	269	.	.	.	O

B-Organism_substance	270	277	Samples	Sample	NNS	B-NP
O	278	282	were	be	VBD	B-VP
O	283	290	assayed	assay	VBN	I-VP
O	291	294	for	for	IN	B-PP
O	295	302	glucose	glucose	NN	B-NP
O	302	303	,	,	,	O
O	304	311	lactate	lactate	NN	B-NP
O	311	312	,	,	,	O
O	313	316	and	and	CC	O
O	317	324	insulin	insulin	NN	B-NP
O	325	339	concentrations	concentration	NNS	I-NP
O	340	343	and	and	CC	O
O	344	352	compared	compare	VBN	B-VP
O	353	366	statistically	statistically	RB	B-ADVP
O	367	371	with	with	IN	B-PP
O	372	375	ten	ten	CD	B-NP
O	376	383	control	control	NN	I-NP
O	384	388	dogs	dog	NNS	I-NP
O	389	391	of	of	IN	B-PP
O	392	399	similar	similar	JJ	B-NP
O	400	406	weight	weight	NN	I-NP
O	407	410	and	and	CC	I-NP
O	411	414	age	age	NN	I-NP
O	415	425	undergoing	undergo	VBG	B-VP
O	426	428	an	an	DT	B-NP
O	429	438	identical	identical	JJ	I-NP
O	439	447	dextrose	dextrose	NN	I-NP
O	448	457	challenge	challenge	NN	I-NP
O	457	458	.	.	.	O

O	459	463	Dogs	Dog	NNS	B-NP
O	464	468	with	with	IN	B-PP
B-Cancer	469	477	lymphoma	lymphoma	NN	B-NP
O	478	481	had	have	VBD	B-VP
O	482	489	similar	similar	JJ	B-NP
O	490	497	glucose	glucose	NN	I-NP
O	498	507	tolerance	tolerance	NN	I-NP
O	508	514	curves	curve	NNS	I-NP
O	515	519	when	when	WRB	B-ADVP
O	520	528	compared	compare	VBN	B-PP
O	529	533	with	with	IN	B-PP
O	534	542	controls	control	NNS	B-NP
O	542	543	.	.	.	O

O	544	551	Lactate	Lactate	NN	B-NP
O	552	566	concentrations	concentration	NNS	I-NP
O	567	571	were	be	VBD	B-VP
O	572	585	significantly	significantly	RB	B-ADJP
O	586	592	higher	high	JJR	I-ADJP
O	593	594	(	(	(	O
O	594	595	P	P	NN	B-NP
O	596	600	less	less	JJR	B-NP
O	601	605	than	than	IN	I-NP
O	606	607	0	0	CD	I-NP
O	607	608	.	.	.	I-NP
O	608	611	001	001	CD	I-NP
O	611	612	)	)	)	O
O	613	615	at	at	IN	B-PP
O	616	624	baseline	baseline	NN	B-NP
O	625	628	and	and	CC	O
O	629	632	all	all	DT	B-NP
O	633	637	time	time	NN	I-NP
O	638	645	periods	period	NNS	I-NP
O	646	648	of	of	IN	B-PP
O	649	652	the	the	DT	B-NP
O	653	660	glucose	glucose	NN	I-NP
O	661	670	tolerance	tolerance	NN	I-NP
O	671	675	test	test	NN	I-NP
O	676	678	in	in	IN	B-PP
O	679	683	dogs	dog	NNS	B-NP
O	684	688	with	with	IN	B-PP
B-Cancer	689	697	lymphoma	lymphoma	NN	B-NP
O	698	702	when	when	WRB	B-ADVP
O	703	711	compared	compare	VBN	B-PP
O	712	716	with	with	IN	B-PP
O	717	725	controls	control	NNS	B-NP
O	725	726	.	.	.	O

O	727	731	Rise	Rise	NN	B-NP
O	732	734	in	in	IN	B-PP
O	735	742	lactate	lactate	NN	B-NP
O	743	757	concentrations	concentration	NNS	I-NP
O	758	762	over	over	IN	B-PP
O	763	771	baseline	baseline	NN	B-NP
O	772	778	levels	level	NNS	I-NP
O	779	781	in	in	IN	B-PP
O	782	785	the	the	DT	B-NP
O	786	791	first	first	JJ	I-NP
O	792	794	30	30	CD	I-NP
O	795	802	minutes	minute	NNS	I-NP
O	803	805	of	of	IN	B-PP
O	806	809	the	the	DT	B-NP
O	810	817	glucose	glucose	NN	I-NP
O	818	827	tolerance	tolerance	NN	I-NP
O	828	832	test	test	NN	I-NP
O	833	837	were	be	VBD	B-VP
O	838	851	significantly	significantly	RB	B-ADJP
O	852	858	higher	high	JJR	I-ADJP
O	859	861	in	in	IN	B-PP
O	862	866	dogs	dog	NNS	B-NP
O	867	871	with	with	IN	B-PP
B-Cancer	872	880	lymphoma	lymphoma	NN	B-NP
O	881	882	(	(	(	O
O	882	883	P	P	NN	B-NP
O	884	885	=	=	SYM	B-VP
O	886	887	0	0	CD	B-NP
O	887	888	.	.	SYM	I-NP
O	888	891	011	011	CD	I-NP
O	891	892	)	)	)	O
O	892	893	.	.	.	O

O	894	901	Insulin	Insulin	NN	B-NP
O	902	916	concentrations	concentration	NNS	I-NP
O	917	921	were	be	VBD	B-VP
O	922	935	significantly	significantly	RB	B-ADJP
O	936	942	higher	high	JJR	I-ADJP
O	943	944	(	(	(	O
O	944	945	P	P	NN	B-NP
O	946	950	less	less	JJR	B-NP
O	951	955	than	than	IN	I-NP
O	956	957	0	0	CD	I-NP
O	957	958	.	.	.	I-NP
O	958	961	001	001	CD	I-NP
O	961	962	)	)	)	O
O	963	965	at	at	IN	B-PP
O	966	974	baseline	baseline	NN	B-NP
O	975	978	and	and	CC	O
O	979	981	at	at	IN	B-PP
O	982	985	the	the	DT	B-NP
O	986	987	5	5	CD	I-NP
O	987	988	-	-	HYPH	I-NP
O	988	989	,	,	,	O
O	990	992	45	45	CD	B-NP
O	992	993	-	-	HYPH	B-ADVP
O	993	994	,	,	,	O
O	995	997	60	60	CD	B-NP
O	997	998	-	-	HYPH	B-ADJP
O	998	999	,	,	,	O
O	1000	1003	and	and	CC	O
O	1004	1006	90	90	CD	B-NP
O	1006	1007	-	-	HYPH	I-NP
O	1007	1013	minute	minute	NN	I-NP
O	1014	1018	time	time	NN	I-NP
O	1019	1026	periods	period	NNS	I-NP
O	1027	1029	of	of	IN	B-PP
O	1030	1033	the	the	DT	B-NP
O	1034	1041	glucose	glucose	NN	I-NP
O	1042	1051	tolerance	tolerance	NN	I-NP
O	1052	1056	test	test	NN	I-NP
O	1057	1059	in	in	IN	B-PP
O	1060	1064	dogs	dog	NNS	B-NP
O	1065	1069	with	with	IN	B-PP
B-Cancer	1070	1078	lymphoma	lymphoma	NN	B-NP
O	1078	1079	.	.	.	O

O	1080	1084	Rise	Rise	NN	B-NP
O	1085	1087	in	in	IN	B-PP
O	1088	1095	insulin	insulin	NN	B-NP
O	1096	1110	concentrations	concentration	NNS	I-NP
O	1111	1115	over	over	IN	B-PP
O	1116	1124	baseline	baseline	NN	B-NP
O	1125	1127	in	in	IN	B-PP
O	1128	1131	the	the	DT	B-NP
O	1132	1137	first	first	JJ	I-NP
O	1138	1139	5	5	CD	I-NP
O	1140	1147	minutes	minute	NNS	I-NP
O	1148	1150	of	of	IN	B-PP
O	1151	1154	the	the	DT	B-NP
O	1155	1162	glucose	glucose	NN	I-NP
O	1163	1172	tolerance	tolerance	NN	I-NP
O	1173	1177	test	test	NN	I-NP
O	1178	1182	were	be	VBD	B-VP
O	1183	1187	also	also	RB	B-ADVP
O	1188	1201	significantly	significantly	RB	B-ADJP
O	1202	1209	greater	great	JJR	I-ADJP
O	1210	1212	in	in	IN	B-PP
O	1213	1217	dogs	dog	NNS	B-NP
O	1218	1222	with	with	IN	B-PP
B-Cancer	1223	1231	lymphoma	lymphoma	NN	B-NP
O	1232	1233	(	(	(	O
O	1233	1234	P	P	NN	B-NP
O	1235	1236	=	=	SYM	B-VP
O	1237	1238	0	0	CD	B-NP
O	1238	1239	.	.	.	O
O	1239	1242	021	021	CD	B-NP
O	1242	1243	)	)	)	O
O	1243	1244	.	.	.	O

O	1245	1250	These	These	DT	B-NP
O	1251	1258	results	result	NNS	I-NP
O	1259	1267	indicate	indicate	VBP	B-VP
O	1268	1280	carbohydrate	carbohydrate	NN	B-NP
O	1281	1291	metabolism	metabolism	NN	I-NP
O	1292	1294	is	be	VBZ	B-VP
O	1295	1302	altered	alter	VBN	I-VP
O	1303	1305	in	in	IN	B-PP
O	1306	1310	dogs	dog	NNS	B-NP
O	1311	1315	with	with	IN	B-PP
B-Cancer	1316	1324	lymphoma	lymphoma	NN	B-NP
O	1324	1325	.	.	.	O

O	1326	1330	Many	Many	JJ	B-NP
O	1331	1333	of	of	IN	B-PP
O	1334	1339	these	these	DT	B-NP
O	1340	1351	alterations	alteration	NNS	I-NP
O	1352	1360	parallel	parallel	VBP	B-VP
O	1361	1366	those	those	DT	B-NP
O	1367	1375	observed	observe	VBN	B-VP
O	1376	1378	in	in	IN	B-PP
O	1379	1384	human	human	JJ	B-NP
O	1385	1393	patients	patient	NNS	I-NP
O	1394	1403	suffering	suffer	VBG	B-VP
O	1404	1408	from	from	IN	B-PP
B-Organism_substance	1409	1415	cancer	cancer	NN	B-NP
I-Organism_substance	1416	1424	cachexia	cachexia	NN	I-NP
O	1425	1431	making	make	VBG	B-VP
O	1432	1438	canine	canine	JJ	B-NP
B-Cancer	1439	1447	lymphoma	lymphoma	NN	I-NP
O	1448	1449	a	a	DT	B-NP
O	1450	1459	potential	potential	JJ	I-NP
O	1460	1465	model	model	NN	I-NP
O	1466	1469	for	for	IN	B-PP
O	1470	1477	further	further	JJ	B-NP
O	1478	1483	study	study	NN	I-NP
O	1484	1486	of	of	IN	B-PP
O	1487	1490	the	the	DT	B-NP
O	1491	1503	pathogenesis	pathogenesis	NN	I-NP
O	1504	1507	and	and	CC	I-NP
O	1508	1515	therapy	therapy	NN	I-NP
O	1516	1518	of	of	IN	B-PP
B-Organism_substance	1519	1525	cancer	cancer	NN	B-NP
I-Organism_substance	1526	1534	cachexia	cachexia	NN	I-NP
O	1534	1535	.	.	.	O

